Studio osservazionale, per valutare la ritenzione del trattamento di un biosimilare di Adalimumab (Hyrimoz®) in pazienti con IBD in un contesto di vita reale (HYRISS)
Uno studio multicentrico, internazionale, prospettico, non interventistico, osservazionale, per valutare la conservazione del trattamento di un biosimilare Adalimumab (Hyrimoz®) in pazienti con IBD in un contesto di vita reale
An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The main purpose of this non-interventional study is to assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation in Inflammatory Bowel Disease (IBD) patients.
Primary data will be collected at each data collection time point (visits will be according to local clinical practice). Data will be collected based on the information reported in the medical records. This study does not impose a therapy protocol, procedure or change in routine medical practice. Apart from self-administered questionnaires, no additional examinations or assessments are required, consequently there are no additional medical risks for the patients. The total duration of the study will be 36 months (3 years). The recruitment period will be for 2 years with individual patient follow-up for up to 1 year.
It is expected that patients will visit their physicians at regular intervals depending on local specific clinical practices. Four time points for data collection will be defined:
- T0 (patient inclusion in the study and Baseline characteristics).
- T1 (3-month follow-up ± 1 month).
- T2 (6-month follow-up and primary criteria -2/+3 months).
- T3 (12-month follow-up -3/+2 months).
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
-
Aalst, Belgio
- Sandoz Investigational Site Belgium
-
Antwerp, Belgio
- Sandoz Investigational Site Belgium
-
Bonheiden, Belgio
- Sandoz Investigational Site Belgium
-
Brussels, Belgio
- Sandoz Investigational Site Belgium
-
Eeklo, Belgio
- Sandoz Investigational Site Belgium
-
Ghent, Belgio
- Sandoz Investigational Site Belgium
-
Herentals, Belgio
- Sandoz Investigational Site Belgium
-
Kortrijk, Belgio
- Sandoz Investigational Site Belgium
-
Liège, Belgio
- Sandoz Investigational Site Belgium
-
Namur, Belgio
- Sandoz Investigational Site Belgium
-
Seraing, Belgio
- Sandoz Investigational Site Belgium
-
Sint-Niklaas, Belgio
- Sandoz Investigational Site Belgium
-
Tongeren, Belgio
- Sandoz Investigational Site Belgium
-
-
-
-
-
Amiens, Francia
- Sandoz Investigational Site France
-
Auxerre, Francia
- Sandoz Investigational Site France
-
Bayonne, Francia
- Sandoz Investigational Site France
-
Beauvais, Francia
- Sandoz Investigational Site France
-
Brest, Francia
- Sandoz Investigational Site France
-
Caen, Francia
- Sandoz Investigational Site France
-
Castelnau-le-Lez, Francia
- Sandoz Investigational Site France
-
Clermont-Ferrand, Francia
- Sandoz Investigational Site France
-
Clichy, Francia
- Sandoz Investigational Site France
-
Cornebarrieu, Francia
- Sandoz Investigational Site France
-
Créteil, Francia
- Sandoz Investigational Site France
-
Gien, Francia
- Sandoz Investigational Site France
-
Le Coudray, Francia
- Sandoz Investigational Site France
-
Le Kremlin-Bicêtre, Francia
- Sandoz Investigational Site France
-
Lille, Francia
- Sandoz Investigational Site France
-
Lyon, Francia
- Sandoz Investigational Site France
-
Marseille, Francia
- Sandoz Investigational Site France
-
Montpellier, Francia
- Sandoz Investigational Site France
-
Nancy, Francia
- Sandoz Investigational Site France
-
Neuilly-sur-Seine, Francia
- Sandoz Investigational Site France
-
Nice, Francia
- Sandoz Investigational Site France
-
Nîmes, Francia
- Sandoz Investigational Site France
-
Orléans, Francia
- Sandoz Investigational Site France
-
Paris, Francia
- Sandoz Investigational Site France
-
Pessac, Francia
- Sandoz Investigational Site France
-
Pierre-Bénite, Francia
- Sandoz Investigational Site France
-
Poitiers, Francia
- Sandoz Investigational Site France
-
Pringy, Francia
- Sandoz Investigational Site France
-
Reims, Francia
- Sandoz Investigational Site France
-
Rennes, Francia
- Sandoz Investigational Site France
-
Saint-Etienne, Francia
- Sandoz Investigational Site France
-
Saint-Nazaire, Francia
- Sandoz Investigational Site France
-
Sarrebourg, Francia
- Sandoz Investigational Site France
-
Toulouse, Francia
- Sandoz Investigational Site France
-
Tours, Francia
- Sandoz Investigational Site France
-
Troyes, Francia
- Sandoz Investigational Site France
-
Vandœuvre-lès-Nancy, Francia
- Sandoz Investigational Site France
-
Vénissieux, Francia
- Sandoz Investigational Site France
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients for whom the investigator has decided to initiate treatment with Hyrimoz® in accordance with the approved SmPC and local clinical practice, will be eligible to participate in the study.
Descrizione
Inclusion Criteria:
Patients must meet all of the following criteria at Baseline:
-
Patients initiating Hyrimoz® treatment.
-
Patients with a confirmed diagnosis (following local recommendations) of one of these indications: CD or UC.
-
Patients ≥ 18 years of age.
-
Patient in whom the decision to initiate Hyrimoz® (naïve population) or to switch (switch population) from reference adalimumab to Hyrimoz® was accorded with his physician before the proposal to participate in the study.
-
Patients meeting one of the following criteria:
- Referred to as "switched patients": Patients treated continuously with adalimumab (other than Hyrimoz®) for at least 6 months, with an indication for continuing treatment with adalimumab at any therapeutic dose (physician's decision) and who have controlled stable disease for at least 3 months before study enrollment (according to the physician's criteria).
- Referred to as "biologic-naive patients": Patients who had an inadequate response or contraindications to conventional therapy with no exposure to any biological medicine and targeted therapies and started Hyrimoz® as a first-line biologic therapy according to the summary of product characteristics (SmPC).
-
Patients able to complete and understand the self-administered questionnaires.
-
Patients who have been informed and have provided a signed written consent as per local regulations prior to participation in the study
Exclusion Criteria:
Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
- Patients enrolled in an ongoing interventional study.
- Patients with any contraindications to Hyrimoz® according to the SmPC.
- Patients at imminent risk of scheduled intestinal surgery (stenosis, strictures, internal fistula).
- Use of any investigational drug in last 6 months prior to enrollment.
- Patient received any biological medicine or targeted therapy, in case of " biologic-naive patient ",
- Patient received adalimumab for less than 6 months or have controlled disease for less than 3 months, in case of "switched patient".
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Hyrimoz
Patients prescribed with Hyrimoz |
There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of patients who remain on Hyrimoz® at 6 months after treatment initiation
Lasso di tempo: Up to 6 months
|
Assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation |
Up to 6 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of patients who discontinue Hyrimoz
Lasso di tempo: 6 months, 12 months
|
Percentage of patients who discontinue Hyrimoz® at T2 and T3 due to:
|
6 months, 12 months
|
|
Percentage of patients with high level of treatment satisfaction using TSQM-9 questionnaire
Lasso di tempo: 3 months, 6 months, 12 months
|
To assess patients' treatment satisfaction (based on 9-item Treatment Satisfaction Questionnaire for Medication [TSQM 9], the percentage of patients with high level of treatment satisfaction (score ≥ 39) will be collected. The TSQM-9 is declined with 9 questions about patient treatment satisfaction. Each answer gives a number of points depending of the question and the answer. The final score is the sum of points in each question. This questionnaire score from 9 to 59 points. In HYRISS study, we estimate that patient with < 39 pts in TSQM-9 are considered with a low satisfaction for the medication (satisfaction under 60%). |
3 months, 6 months, 12 months
|
|
Percentage of patients with high level of treatment adherence using adapted CQR5 questionnaire
Lasso di tempo: Baseline, 3 months, 6 months, 12 months
|
To assess adherence/compliance to treatment (based on 5 item Compliance Questionnaire for Rheumatology [CQR5] adapted for gastroenterologist), percentage of patients with high level of treatment adherence (score ≥ 15) using adapted CQR5 questionnaire will be collected. The CQR5 is declined with 5 questions about patient compliance to the treatment. Each answer gives from 1 to 4 points depending of the answer. The final score is the sum of points in each question. This questionnaire score from 5 (very low compliance) to 20 points (very strong compliance). |
Baseline, 3 months, 6 months, 12 months
|
|
Percentage of patients with the perception of a high level of disease activity using VAS scale
Lasso di tempo: Baseline, 3 months, 6 months, 12 months
|
To assess the patient's reported disease activity, percentage of patients with the perception of a high level (score ≥ 6) of disease activity will be collected using visual analog scale [VAS]. This visual analogue scale (VAS) is an instrument designed to document the disease activity. Patients are asked to rate their disease activity on a visual analogue scale (VAS): How active has your disease been this week? From 0 (Not active at all) to 10 cm (Extremely active). |
Baseline, 3 months, 6 months, 12 months
|
|
Percentage of patients with a good perception about biosimilars using VAS scale
Lasso di tempo: Baseline
|
To assess the patient's reported perception about biosimilars at the inclusion visit, percentage of patients with a good perception (score ≥ 6) about biosimilars using VAS scale will be measured. This visual analogue scale (VAS) is an instrument designed to document the perception of the patient about biosimilar. Patients are asked to rate their perception of biosimilar medicine on a visual analogue scale (VAS): Are you confident in using biosimilar? From 0 (I have no confidence at all) to 10 cm (I have a great confidence). |
Baseline
|
|
Percentage of patients in remission
Lasso di tempo: Baseline, 3 months, 6 months, 12 months
|
Remission defined as Harvey-Bradshaw Index [HBI] ≤ 4 [for Crohn's Disease] or partial Mayo score ≤ 1 [for Ulcerative Colitis] |
Baseline, 3 months, 6 months, 12 months
|
|
Crohn's disease activity measurement: Harvey Bradshaw Index [HBI]
Lasso di tempo: Up to 12 months
|
Crohn's disease activity will be measured with HBI score. Score is interpreted: <4: Remission 4-7: Mild disease 8-16: Moderate disease >16: Severe disease |
Up to 12 months
|
|
Ulcerative colitis activity measurement: partial Mayo calculation score
Lasso di tempo: Up to 12 months
|
Ulcerative colitis activity will be measured using partial Mayo calculation score. Score is interpreted: ≤ 1: Remission 2 - 4: Low activity disease 5 -6: Moderate disease 7 - 9: Severe disease |
Up to 12 months
|
|
Pattern of Hyrimoz® utilization
Lasso di tempo: Up to 12 months
|
Pattern of Hyrimoz® utilization to be collected |
Up to 12 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CGP2017IC01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .